SCHEMBL3563271

SCHEMBL3563271

Cc1cc2ccccc2n1S(=O)(=O)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.56
CA9 Q16790 3/20 0.56
CA2 P00918 1/20 0.56
BRD4 O60885 1/20 0.51
ALDH1A1 P00352 2/20 0.51
LMNA P02545 2/20 0.51
RECQL P46063 1/20 0.51
MAPT P10636 1/20 0.51
NOD1 Q9Y239 5/20 0.50
NOD2 Q9HC29 4/20 0.50
HTR6 P50406 2/20 0.50
MEN1 O00255 1/20 0.50
HPGD P15428 1/20 0.50
TSHR P16473 1/20 0.50
HTT P42858 1/20 0.50
KMT2A Q03164 1/20 0.50
CXCL8 P10145 1/20 0.49
SRC P12931 1/20 0.47
ALOX5 P09917 1/20 0.47
CCR2 P41597 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28414053 0.90 NOD1 (0.61) CA12CA9CA2ALDH1A1LMNA
SCHEMBL4794912 0.87 NOD1 (0.63) CA12CA9CA2NOD1NOD2
SCHEMBL3565182 0.85 PPARG (0.61) CA12CA9CA2BRD4ALDH1A1
SCHEMBL6383467 0.82 HTR6 (0.58) CA12CA9CA2BRD4ALDH1A1
SCHEMBL3562156 0.82 PPARG (0.61) BRD4NOD1NOD2HTR6ALDH3A1
SCHEMBL3563978 0.82 BRD4 (0.49) CA12CA9CA2BRD4ALDH1A1
SCHEMBL3560737 0.82 PTGDR2 (0.53) BRD4ALDH1A1LMNARECQLMAPT
SCHEMBL12968247 0.82 BRD4 (0.49) CA12CA9CA2BRD4ALDH1A1
SCHEMBL28228343 0.82 CA12 (0.56) CA12CA9CA2ALDH1A1LMNA
SCHEMBL10199579 0.81 RECQL (0.58) CA12CA9CA2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3204360-B1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2020-08-26 EP disclosed
CN-108558862-A A kind of synthetic method and intermediate of anti-leukocythemia tumor cell viability molecule 上海工程技术大学 2018-09-21 CN disclosed
US-20170312292-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF WUXI APPTEC (SHANGHAI) CO. LTD (CN) 2017-11-02 US disclosed
US-20170312292-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF WUXI APPTEC (SHANGHAI) CO. LTD (CN) 2017-11-02 US disclosed
US-20160367693-A1 Selective Arylation of Dichalcogenides in Biomolecules NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-12-22 US disclosed
WO-2016205798-A1 SELECTIVE ARYLATION OF DICHALCOGENIDES IN BIOMOLECULES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2016-12-22 WO disclosed
EP-1567492-B1 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LTD (IN) 2013-05-22 EP disclosed
US-8426453-B2 Treatment of a stomach or small intestine ulcer with 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-1,3-thiazole-5-carboxylic acid ASTELLAS PHARMA INC. (JP) 2013-04-23 US disclosed
US-8426453-B2 Treatment of a stomach or small intestine ulcer with 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-1,3-thiazole-5-carboxylic acid ASTELLAS PHARMA INC. (JP) 2013-04-23 US disclosed
US-8067446-B2 Methods for treating an ulcer of the small intestine and stomach ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-20080033007-A1 Substituted Tetrahydroisoquinoline Compounds for Cancer Therapy MILLER DUANE D 2008-02-07 US disclosed
EP-1880993-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-01-23 EP disclosed
US-20070293675-A1 Novel Inhibitors Of Beta-Lactamase METHYLGENE, INC. (CA) 2007-12-20 US disclosed
US-20070293675-A1 Novel Inhibitors Of Beta-Lactamase METHYLGENE, INC. (CA) 2007-12-20 US disclosed
US-20070270460-A1 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, METHODS OF MAKING, AND THEIR USE MILLER DUANE D 2007-11-22 US disclosed
US-7259172-B2 phenyl or thien-2-yl substituted amide methyl phosphonate or phosphonyl halide derivatives; do not require a beta -lactam pharmacophore; bactericides; antibiotic resistance METHYLGENE INC. (CA) 2007-08-21 US disclosed
US-7259172-B2 phenyl or thien-2-yl substituted amide methyl phosphonate or phosphonyl halide derivatives; do not require a beta -lactam pharmacophore; bactericides; antibiotic resistance METHYLGENE INC. (CA) 2007-08-21 US disclosed
US-7241774-B2 Substituted tetrahydroisoquinoline compounds, methods of making, and their use UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2007-07-10 US disclosed
US-20060173193-A1 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LIMITED (IN) 2006-08-03 US disclosed
CN-1720227-A N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LTD (IN) 2006-01-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033007-A1 Substituted Tetrahydroisoquinoline Compounds for Cancer Therapy BAD, TP53, MCL1 CA12 4086/4885CA9 3737/4885CA2 4318/4885
US-20160367693-A1 Selective Arylation of Dichalcogenides in Biomolecules SCLY, SELENOI, TPO CA12 693/4885CA9 2082/4885CA2 3241/4885
US-20070270460-A1 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, METHODS OF MAKING, AND THEIR USE BAX, CASP3, BAD CA12 4051/4885CA9 3045/4885CA2 3391/4885
US-20170312292-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, CREBBP, HDAC1 CA12 3821/4885CA9 3913/4885CA2 3156/4885
US-20060173193-A1 N-arylsulfonyl-3-aminoalkoxyindoles HTR3C, HTR3A, AANAT CA12 4416/4885CA9 4205/4885CA2 3663/4885
US-20070293675-A1 Novel Inhibitors Of Beta-Lactamase MGAM, LSS, CYP51A1 CA12 3776/4885CA9 1091/4885CA2 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.